Subclinical Thyroid Disease: Scientific Review and Guidelines for Diagnosis and Management | Atrial Fibrillation | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado Thyroid Disease Prevalence Study.  Arch Intern Med.2000;160:526-534. Scholar
Cooper DS. Clinical practice: subclinical hypothyroidism.  N Engl J Med.2001;345:260-265. Scholar
Toft AD. Clinical practice: subclinical hyperthyroidism.  N Engl J Med.2001;345:512-516. Scholar
Surks MI, Ocampo E. Subclinical thyroid disease.  Am J Med.1996;100:217-223. Scholar
McDermott MT, Ridgway EC. Clinical perspective: subclinical hypothyroidism is mild thyroid failure and should be treated.  J Clin Endocrinol Metab.2001;86:4585-4590. Scholar
Chu JW, Crapo LM. Clinical perspective: the treatment of subclinical hypothyroidism is seldom necessary.  J Clin Endocrinol Metab.2001;86:4591-4599. Scholar
Baskin HJ. American Association of Clinical Endocrinologists guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism.  Endocr Practice.2002;8:458-467.Google Scholar
Ladenson PW, Singer PA, Ain KB.  et al.  American Thyroid Association guidelines for detection of thyroid dysfunction.  Arch Intern Med.2000;160:1573-1575. Scholar
US Preventive Services Task Force, Agency for Healthcare Research and Quality Web site.  Third USPSTF strength of overall evidence. Available at: Accessed December 9, 2002.
Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyrotropin (TSH) assays.  Clin Chem.1996;42:2051-2052. Scholar
National Academy of Clinical Biochemistry Web site.  NACB laboratory medicine practice guidelines. Available at: Accessed December 9, 2002.
Ross DS. Serum thyroid-stimulating hormone measurement for assessment of thyroid function and disease.  Endocrinol Metab Clin North Am.2001;30:245-264. Scholar
Surks MI, Oppenheimer JH. Metabolism of phenolic- and tyrosyl-ring labeled L-thyroxine in human beings and rats.  J Clin Endocrinol Metab.1971;33:612-618. Scholar
Wong ET, Bradley SG, Schultz AL. Elevations of thyroid-stimulating hormone during acute nonthyroidal illness.  Arch Intern Med.1981;141:873-875. Scholar
Bhakri HL, Fisher R, Khadri A, MacMahon DG. Longitudinal study of thyroid function in acutely ill elderly patients using a sensitive TSH assay—defer testing until recovery.  Gerontology.1990;36:140-144. Scholar
Gharib H, Hodgson SF, Gastineau CF, Scholz DA, Smith LA. Reversible hypothyroidism in Addison's disease.  Lancet.1972;2:734-736. Scholar
Ismail AA, Burr WA, Walker PL. Acute changes in serum thyrotropin in treated Addison's disease.  Clin Endocrinol (Oxf).1989;30:225-230. Scholar
Ladenson PW, Braverman LE, Mazzaferri EL.  et al.  Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma.  N Engl J Med.1997;337:888-896. Scholar
Brennan MD, Klee GG, Preissner CM, Hay ID. Heterophilic serum antibodies: a cause for falsely elevated serum thyrotropin levels.  Mayo Clin Proc.1987;62:894-898. Scholar
Wood JM, Gordon DL, Rudinger AN, Brooks MM. Artifactual elevation of thyroid-stimulating hormone.  Am J Med.1991;90:261-262. Scholar
Ward G, McKinnon L, Badrick T, Hickman PE. Heterophilic antibodies remain a problem for the immunoassay laboratory.  Am J Clin Pathol.1997;108:417-421. Scholar
Beck-Peccoz P, Amr S, Menezes-Ferreira MM, Faglia G, Weintraub BD. Decreased receptor binding of biologically inactive thyrotropin in central hypothyroidism: effect of treatment with thyrotropin-releasing hormone.  N Engl J Med.1985;312:1085-1090. Scholar
Hollowell JG, Staehling NW, Flanders WD.  et al.  Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).  J Clin Endocrinol Metab.2002;87:489-499. Scholar
Vanderpump MP, Tunbridge WM, French JM.  et al.  The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey.  Clin Endocrinol (Oxf).1995;43:55-68. Scholar
Uy HL, Reasner CA, Samuels MH. Pattern of recovery of the hypothalamic-pituitary thyroid axis following radioiodine therapy in patients with Graves' disease.  Am J Med.1995;99:173-179. Scholar
Glinoer D, De Nayer P, Bourdoux P.  et al.  Regulation of maternal thyroid during pregnancy.  J Clin Endocrinol Metab.1990;71:276-282. Scholar
Wehmann RE, Gregerman RI, Burns WH, Saral R, Santos GW. Suppression of thyrotropin in the low-thyroxine state of severe nonthyroidal illness.  N Engl J Med.1985;312:546-552. Scholar
Franklyn JA, Black EG, Betteridge J, Sheppard MC. Comparison of second and third generation methods for measurement of serum thyrotropin in patients with overt hyperthyroidism, patients receiving thyroxine therapy and those with non-thyroidal illness.  J Clin Endocrinol Metab.1994;78:1368-1371. Scholar
Van den Berghe G, de Zegher F, Lauwers P. Dopamine and the sick euthyroid syndrome in critical illness.  Clin Endocrinol (Oxf).1994;41:731-737. Scholar
Benker G, Raida M, Olbricht T, Wagner R, Reinhardt W, Reinwein D. TSH secretion in Cushing's syndrome: relation to glucocorticoid excess, diabetes, goiter, and the "sick euthyroid syndrome."  Clin Endocrinol (Oxf).1990;33:777-786. Scholar
Hangaard J, Andersen M, Grodum E, Koldkjaer O, Hagen C. Pulsatile thyrotropin secretion in patients with Addison's disease during variable glucocorticoid therapy.  J Clin Endocrinol Metab.1996;81:2502-2507. Scholar
Lee E, Chen P, Rao H, Lee J, Burmeister LA. Effect of acute high dose dobutamine administration on serum thyrotropin (TSH).  Clin Endocrinol (Oxf).1999;50:487-492. Scholar
Sawin CT, Castelli WP, Hershman JM.  et al.  The aging thyroid: thyroid deficiency in the Framingham Study.  Arch Intern Med.1985;145:1386-1388. Scholar
Parle JV, Franklyn JA, Cross KW, Jones SC, Sheppard MC. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom.  Clin Endocrinol (Oxf).1991;34:77-83. Scholar
Robuschi G, Safran M, Braverman LE.  et al.  Hypothyroidism in the elderly.  Endocr Rev.1987;8:142-153. Scholar
Kung AW, Janus ED. Thyroid dysfunction in ambulatory elderly Chinese subjects in an area of borderline iodine intake.  Thyroid.1996;6:111-114. Scholar
Sawin CT. Subclinical hypothyroidism in older persons.  Clin Geriatr Med.1995;11:231-238. Scholar
Laurberg P, Pedersen KM, Vestergaard H.  et al.  High incidence of multinodular toxic goiter in the elderly population in a low iodine intake area vs high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland.  J Intern Med.1991;229:415-420. Scholar
Ross DS, Daniels GH, Gouveia D. The use and limitations of a chemiluminescent thyrotropin assay as a single thyroid function test in an outpatient endocrine clinic.  J Clin Endocrinol Metab.1990;71:764-769. Scholar
Parle JV, Franklyn JA, Cross KW, Jones SR, Sheppard MC. Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment.  Br J Gen Pract.1993;43:107-109. Scholar
Sawin CT, Geller A, Kaplan MM.  et al.  Low serum thyrotropin (thyroid-stimulating hormone) in older persons without hyperthyroidism.  Arch Intern Med.1991;151:165-168. Scholar
Stott DJ, McLellan AR, Finlayson J.  et al.  Elderly patients with suppressed serum TSH but normal free thyroid hormone levels usually have mild thyroid overactivity and are at increased risk of developing overt hyperthyroidism.  QJM.1991;78:77-84. Scholar
Sawin CT, Geller A, Wolf PA.  et al.  Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons.  N Engl J Med.1994;331:1249-1252. Scholar
Stanbury JB, Ermans AE, Bourdoux P.  et al.  Iodine-induced hyperthyroidism: occurrence and epidemiology.  Thyroid.1998;8:83-100. Scholar
Monzani F, DiBello V, Caraccio N.  et al.  Effect of levothyroxine on cardiac function and structure.  J Clin Endocrinol Metab.2001;86:1110-1115. Scholar
Kahaly GJ. Cardiovascular and atherogenic aspects of subclinical hypothyroidism.  Thyroid.2000;10:665-679. Scholar
Biondi B, Fazio S, Palmieri EA.  et al.  Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism.  J Clin Endocrinol Metab.1999;84:2064-2067. Scholar
Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of subclinical thyroid dysfunction on the heart.  Ann Intern Med.2002;137:904-914. Scholar
Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study.  Ann Intern Med.2000;132:270-278. Scholar
Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study.  Lancet.2001;358:861-865. Scholar
Danese MD, Ladenson PW, Meinert CL, Powe NR. Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature.  J Clin Endocrinol Metab.2000;85:2993-3001. Scholar
Kanaya A, Harris F, Volpato S.  et al.  Association between thyroid dysfunction and total cholesterol level in an older biracial population.  Arch Intern Med.2002;162:773-779. Scholar
Zulewski H, Muller B, Exer P, Miserez AR, Staub JJ. Estimation of tissue hypothyroidism by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls.  J Clin Endocrinol Metab.1997;82:771-776. Scholar
Monzani F, Caraccio N, DelGuerra P.  et al.  Neuromuscular symptoms and dysfunction in subclinical hypothyroid patients: beneficial effect of L-T4 replacement therapy.  Clin Endocrinol (Oxf).1999;51:237-242. Scholar
Cooper DS, Halpern R, Wood LC, Levin AA, Ridgway EC. L-thyroxine therapy in subclinical hypothyroidism: a double-blind, placebo-controlled trial.  Ann Intern Med.1984;101:18-24. Scholar
Meier C, Staub JJ, Roth CB.  et al.  TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double-blind, placebo-controlled trial (Basel Thyroid Study).  J Clin Endocrinol Metab.2001;86:4860-4866. Scholar
Kong WM, Sheikh MH, Lumb PJ.  et al.  A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism.  Am J Med.2002;112:348-354. Scholar
Bemben DA, Hamm RM, Morgan L, Winn P, Davis A, Barton E. Thyroid disease in the elderly, part 2: predictability of subclinical hypothyroidism.  J Fam Pract.1994;38:583-588. Scholar
Lindeman RD, Schade DS, LaRue A.  et al.  Subclinical hypothyroidism in a biethnic urban community.  J Am Geriatr Soc.1999;47:703-709. Scholar
Nystrom E, Caidahl K, Fager G, Wikkelso C, Lundberg PA, Lindstedt G. A double-blind cross-over 12-month study of L-thyroxine treatment of women with ‘subclinical' hypothyroidism.  Clin Endocrinol (Oxf).1988;29:63-76. Scholar
Huber G, Staub JJ, Meier C.  et al.  Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies.  J Clin Endocrinol Metab.2002;87:3221-3226. Scholar
Caraccio N, Ferrannini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study.  J Clin Endocrinol Metab.2002;87:1533-1538. Scholar
Haddow JE, Palomaki GE, Allan WC.  et al.  Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child.  N Engl J Med.1999;341:549-555. Scholar
Wiersinga WM. Subclinical hypothyroidism and hyperthyroidism, I: prevalence and clinical relevance.  Neth J Med.1995;46:197-204. Scholar
Haden ST, Marqusee E, Utiger RD. Subclinical hyperthyroidism.  Endocrinologist.1996;6:322-327.Google Scholar
Marqusee E, Haden ST, Utiger RD. Subclinical thyrotoxicosis.  Endocrinol Metab Clin North Am.1998;27:37-49. Scholar
Samuels MH. Subclinical thyroid disease in the elderly.  Thyroid.1998;8:803-813. Scholar
Tenerz A, Forberg R, Jansson R. Is a more active attitude warranted in patients with subclinical thyrotoxicosis?  J Intern Med.1990;228:229-233. Scholar
Auer J, Scheiber P, Mische T.  et al.  Subclinical hyperthyroidism as a risk factor for atrial fibrillation.  Am Heart J.2001;142:838-842. Scholar
Biondi B, Fazio S, Cuocolo A.  et al.  Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine.  J Clin Endocrinol Metab.1996;81:4224-4228. Scholar
Biondi B, Palmieri EA, Fazio S.  et al.  Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients.  J Clin Endocrinol Metab.2000;85:4701-4705. Scholar
Shapiro LE, Sievert R, Ong L.  et al.  Minimal cardiac effects in asymptomatic athyrotic patients chronically treated with thyrotropin (TSH)-suppressive doses of L-thyroxine (T4).  J Clin Endocrinol Metab.1997;82:2592-2595. Scholar
Boutin JM, Matte R, D'Amour P.  et al.  Characteristics of patients with normal T3 and T4 and a low TSH response to TRH.  Clin Endocrinol (Oxf).1986;25:579-588. Scholar
Faber J, Wiinberg N, Schiffer S, Mehlsen J. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism.  Eur J Endocrinol.2001;145:391-396. Scholar
Grund FM, Niewoehner CB. Hyperthyroxinemia in patients receiving thyroid replacement therapy.  Arch Intern Med.1989;149:921-924. Scholar
Fazio S, Biondi B, Carella C.  et al.  Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta-blockade.  J Clin Endocrinol Metab.1995;80:2222-2226. Scholar
Rockel M, Teuber J, Kaumeier S.  et al.  Correlation of "latent hyperthyroidism" with psychological and somatic changes [in German].  Klin Wochenschr.1987;65:264-273. Scholar
Schlote B, Schaaf L, Schmidt R.  et al.  Mental and physical state in subclinical hyperthyroidism: investigations in a normal working population.  Biol Psychiatry.1992;32:48-56. Scholar
Foldes J, Tarjan G, Szathmari M.  et al.  Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis?  Clin Endocrinol (Oxf).1993;39:521-527. Scholar
Foldes J, Lakatos P, Zsadanyi J, Horvath C. Decreased serum IGF-I and dehydroepiandrosterone sulphate may be risk factors for the development of reduced bone mass in postmenopausal women with endogenous subclinical hyperthyroidism.  Eur J Endocrinol.1997;136:277-281. Scholar
Faber J, Jensen IW, Petersen L.  et al.  Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women.  Clin Endocrinol (Oxf).1998;48:285-290. Scholar
Mudde AH, Houben AJ, Nieuwenhuijzen Kruseman AC. Bone metabolism during antithyroid drug treatment of endogenous subclinical hyperthyroidism.  Clin Endocrinol (Oxf).1994;41:421-424. Scholar
Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis.  Eur J Endocrinol.1994;130:350-356. Scholar
Uzzan B, Campos J, Cucherat M.  et al.  Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis.  J Clin Endocrinol Metab.1996;81:4278-4289. Scholar
Bauer DC, Nevitt MC, Ettinger B, Stone K. Low thyrotropin levels are not associated with bone loss in older women: a prospective study.  J Clin Endocrinol Metab.1997;82:2931-2936. Scholar
Kumeda Y, Inaba M, Tahara H.  et al.  Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism.  J Clin Endocrinol Metab.2000;85:4157-4161. Scholar
Pantazi H, Papapetrou PD. Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism.  J Clin Endocrinol Metab.2000;85:1099-1106. Scholar
Bauer DC, Ettinger B, Nevitt M, Stone KL.for the Study of Osteoporotic Fractures Research Group.  Risk for fracture in women with low serum levels of thyroid-stimulating hormone.  Ann Intern Med.2001;134:561-568. Scholar
Vestergaard P, Mosekilde L. Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients.  Thyroid.2002;12:411-419. Scholar
Staffurth JS, Gibberd MC, Fui SN. Arterial embolism in thyrotoxicosis with atrial fibrillation.  BMJ.1977;2:688-690. Scholar
Presti CF, Hart RG. Thyrotoxicosis, atrial fibrillation, and embolism, revisited.  Am Heart J.1989;117:976-977. Scholar
Forfar JC, Feek CM, Miller HC, Toft AD. Atrial fibrillation and isolated suppression of the pituitary-thyroid axis: response to specific antithyroid therapy.  Int J Cardiol.1981;1:43-48. Scholar
Leese GP, Jung RT, Guthrie C, Waugh N, Browning MC. Morbidity in patients on L-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH.  Clin Endocrinol (Oxf).1992;37:500-503. Scholar
Hallengren B, Elmstahl B, Berglund J.  et al.  No increase in fracture incidence in patients treated for thyrotoxicosis in Malmo during 1970-74: a 20-year population-based follow-up.  J Intern Med.1999;246:139-144. Scholar
Weetman AP. Graves' disease.  N Engl J Med.2000;343:1236-1248. Scholar
US Preventive Services Task Force.  Guide to Clinical Preventive Services, Third Edition: Periodic UpdatesRockville, Md: Agency for Healthcare Research and Quality; 2002. Publication 02-500.
Scientific Review and Clinical Applications
Clinician's Corner
January 14, 2004

Subclinical Thyroid Disease: Scientific Review and Guidelines for Diagnosis and Management

Author Affiliations

Author Affiliations: Departments of Medicine and Pathology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY (Dr Surks); Center for Primary Care, Prevention, and Clinical Partnerships, Agency for Healthcare Research and Quality, Rockville, Md (Dr Ortiz); Thyroid Unit and Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (Dr Daniels); Veterans Administration, Washington, DC (Dr Sawin); Harvard Medical School, Brigham and Women's Hospital, Division of Women's Health and Department of Medicine, Boston (Dr Col); Department of Medicine, Mount Sinai School of Medicine, New York, NY (Dr Cobin); Division of Medical Sciences, University of Birmingham, Birmingham, England (Dr Franklyn); Endocrinology and Diabetes Division, West Los Angeles VA Medical Center, University of California at Los Angeles School of Medicine (Dr Hershman); Endocrine Section, Washington Hospital Center, Washington, DC (Dr Burman); Department of Medicine, University of Texas Southwestern Medical Center at Dallas (Dr Denke); Research Development, Mayo Foundation, Rochester, Minn (Dr Gorman); Epidemiology, Loyola University Medical School, Chicago, Ill (Dr Cooper); and Cardiac Ultrasound, Washington Hospital Center, and Department of Medicine, Georgetown University Medical College, Washington, DC (Dr Weissman). Dr Denke is now with the University of Texas, San Antonio.

JAMA. 2004;291(2):228-238. doi:10.1001/jama.291.2.228

Context Patients with serum thyroid-stimulating hormone (TSH) levels outside the reference range and levels of free thyroxine (FT4) and triiodothyronine (T3) within the reference range are common in clinical practice. The necessity for further evaluation, possible treatment, and the urgency of treatment have not been clearly established.

Objectives To define subclinical thyroid disease, review its epidemiology, recommend an appropriate evaluation, explore the risks and benefits of treatment and consequences of nontreatment, and determine whether population-based screening is warranted.

Data Sources MEDLINE, EMBASE, Biosis, the Agency for Healthcare Research and Quality, National Guideline Clearing House, the Cochrane Database of Systematic Reviews and Controlled Trials Register, and several National Health Services (UK) databases were searched for articles on subclinical thyroid disease published between 1995 and 2002. Articles published before 1995 were recommended by expert consultants.

Study Selection and Data Extraction A total of 195 English-language or translated papers were reviewed. Editorials, individual case studies, studies enrolling fewer than 10 patients, and nonsystematic reviews were excluded. Information related to authorship, year of publication, number of subjects, study design, and results were extracted and formed the basis for an evidence report, consisting of tables and summaries of each subject area.

Data Synthesis The strength of the evidence that untreated subclinical thyroid disease is associated with clinical symptoms and adverse clinical outcomes was assessed and recommendations for clinical practice developed. Data relating the progression of subclinical to overt hypothyroidism were rated as good, but data relating treatment to prevention of progression were inadequate to determine a treatment benefit. Data relating a serum TSH level higher than 10 mIU/L to elevations in serum cholesterol were rated as fair but data relating to benefits of treatment were rated as insufficient. All other associations of symptoms and benefit of treatment were rated as insufficient or absent. Data relating a serum TSH concentration lower than 0.1 mIU/L to the presence of atrial fibrillation and progression to overt hyperthyroidism were rated as good, but no data supported treatment to prevent these outcomes. Data relating restoration of the TSH level to within the reference range with improvements in bone mineral density were rated as fair. Data addressing all other associations of subclinical hyperthyroid disease and adverse clinical outcomes or treatment benefits were rated as insufficient or absent. Subclinical hypothyroid disease in pregnancy is a special case and aggressive case finding and treatment in pregnant women can be justified.

Conclusions Data supporting associations of subclinical thyroid disease with symptoms or adverse clinical outcomes or benefits of treatment are few. The consequences of subclinical thyroid disease (serum TSH 0.1-0.45 mIU/L or 4.5-10.0 mIU/L) are minimal and we recommend against routine treatment of patients with TSH levels in these ranges. There is insufficient evidence to support population-based screening. Aggressive case finding is appropriate in pregnant women, women older than 60 years, and others at high risk for thyroid dysfunction.